Novo Nordisk A/S (NVO) Stake Raised by Columbia Partners L L C Investment Management

Columbia Partners L L C Investment Management grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 16.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,892 shares of the company’s stock after buying an additional 1,101 shares during the period. Columbia Partners L L C Investment Management’s holdings in Novo Nordisk A/S were worth $379,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the company. Commerce Bank raised its position in shares of Novo Nordisk A/S by 37.3% during the third quarter. Commerce Bank now owns 7,214 shares of the company’s stock valued at $348,000 after buying an additional 1,958 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $267,000. Cambridge Investment Research Advisors Inc. raised its position in shares of Novo Nordisk A/S by 22.7% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 60,680 shares of the company’s stock valued at $2,922,000 after buying an additional 11,206 shares during the last quarter. Bank Hapoalim BM raised its position in shares of Novo Nordisk A/S by 138.4% during the third quarter. Bank Hapoalim BM now owns 12,920 shares of the company’s stock valued at $622,000 after buying an additional 7,500 shares during the last quarter. Finally, First National Trust Co. bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $218,000. Hedge funds and other institutional investors own 6.01% of the company’s stock.

Novo Nordisk A/S (NYSE:NVO) traded up $0.41 during mid-day trading on Friday, hitting $50.91. 1,118,406 shares of the company were exchanged, compared to its average volume of 1,744,110. Novo Nordisk A/S has a 1 year low of $30.89 and a 1 year high of $51.05. The stock has a market capitalization of $129,820.50, a price-to-earnings ratio of 22.23, a PEG ratio of 3.04 and a beta of 0.63.

Several equities research analysts have recently issued reports on NVO shares. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a research report on Tuesday, October 10th. BidaskClub upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. BNP Paribas cut shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research report on Monday, September 25th. Finally, Bank of America Corporation upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, September 6th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. Novo Nordisk A/S has an average rating of “Hold” and an average price target of $55.00.

In other Novo Nordisk A/S news, insider Eric S. Sprott bought 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $8.34 per share, with a total value of $417,000.00. Company insiders own 0.07% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/11/19/novo-nordisk-as-nvo-stake-raised-by-columbia-partners-l-l-c-investment-management.html.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply